Compare CTSO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | EVAX |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 25.8M |
| IPO Year | 2008 | 2020 |
| Metric | CTSO | EVAX |
|---|---|---|
| Price | $0.37 | $3.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.38 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 198.5K | 21.3K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,503,908.00 | N/A |
| Revenue This Year | $10.34 | N/A |
| Revenue Next Year | $22.41 | $328.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.35 | $2.45 |
| 52 Week High | $1.22 | $12.15 |
| Indicator | CTSO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 43.24 |
| Support Level | N/A | $2.97 |
| Resistance Level | $0.74 | $3.61 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.36 | 27.87 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.